RBC Capital raised the firm’s price target on Oxford Biomedica (OXBDF) to 800 GBp from 740 GBp and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXBDF:
- Oxford Biomedica Reports Strong 2024 Financial Performance
- Oxford Biomedica’s Earnings Call Highlights Growth and Challenges
- Oxford Biomedica prepares statements on ‘going concern basis’
- Oxford Biomedica reports FY24 EPS (GPB 41.75) vs. (GPB 163.11) last year
- Oxford Biomedica vice chair Stuart Henderson to retire